Discounted Cash Flow
Tarsus Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $-40.0k | $-4.7m | $-3.8m | 11675.0% | $-1.98 |
| 2020 | $0 (100.0%) | $-26.8m (-474.1%) | $-21.6m (-461.2%) | — | $-4.32 (-118.2%) |
| 2021 | $57.0m | $-13.8m (48.4%) | $3.2m (114.6%) | -24.2% | $-0.67 (84.5%) |
| 2022 | $25.8m (-54.7%) | $-62.1m (-349.1%) | $-49.5m (-1666.6%) | -240.5% (-892.0%) | $-2.52 (-276.1%) |
| 2023 | $17.4m (-32.4%) | $-135.9m (-118.9%) | $-119.0m (-140.2%) | -778.9% (-223.8%) | $-4.62 (-83.3%) |
| 2024 | $183.0m (948.6%) | $-115.6m (15.0%) | $-84.6m (28.9%) | -63.2% (91.9%) | $-3.07 (33.5%) |
| 2025 | $451.4m (146.7%) | $-66.4m (42.5%) | $-22.3m (73.6%) | -14.7% (76.7%) | $-1.59 (48.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.